New drug therapy for eye diseases

Introduction

Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is still an important strategy for many eye diseases, especially for the early stage of glaucoma, dry eye, and thyroid-associated ophthalmopathy. In recent decades, gene editing that can deliver or knock out some specific genes into _targetted tissue also provides us with a bright tool for some congenital eye diseases. The present thematic issue will majorly focus on the new drug development for chronic or congenital eye diseases.

Keywords

Eye disease; Glaucoma; Drug delivery; Signal pathway; Gene editing; Viral vector

Sub-topics

New _targets for IOP reduction; Gene editing for congenital eye diseases; New drug therapy for neovascular retinopathy.